Telavancin a semisynthetic lipoglycopeptide vancomycin-derivative and antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA).
Leadbetter, Michael R.; Adams, Stacy M.; Bazzini, Bettina; Fatheree, Paul R.; Karr, Dane E.; Krause, Kevin M.; Lam, Bernice M. T.; Linsell, Martin S.; Nodwell, Matthew B.; Pace, John L.; Quast, Kelly; Shaw, Jeng-Pyng; Soriano, Elizabeth; Trapp, Sean G.; Villena, Jenny D.; Wu, Terry X.; Christensen, Burton G.; Judice, J. Kevin. Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424). Journal of Antibiotics. Volume 57. Issue 5. Pages 326-336. 2004.
Judice, J. Kevin; Shaw, Jeng-Pyng; Mu, Yongqi; Conner, Michael W. Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin. Assignee Advanced Medicine, Inc., USA. WO 2001082971. (2001).
Schmidt, Donald, Jr.; Sganga, Jeanmarie Donovan. Process for purifying glycopeptide phosphonate derivatives. Assignee Theravance, Inc., USA. WO 2003018608. (2003).
Li, Bingbing; Jiang, Qiao; Chen, Guo; Li, Chengbo; Huang, Lixia. Method for preparing telavancin with vancomycin as raw material. Assignee Livzon New North River Pharmaceutical Co., Ltd., Peop. Rep. China. CN 108948157. (2018).
Huang, Lixia; Li, Bingbing; Jiang, Qiao; Chen, Guo; Li, Chengbo. Method for preparing telavancin with vancomycin as raw material. Assignee Livzon New North River Pharmaceutical Co., Ltd., Peop. Rep. China. CN 108948156. (2018).
